day 6The tenth In September 2022, the Azerbaijan Thalassemia Center and BGI held a virtual signing ceremony for the conclusion of a cooperation agreement. The partnership aims to improve thalassemia screening in Azerbaijan through genetic technology.
In early 2021, on the occasion of the Declaration of “Prevention and Control of Global Hemoglobinopathies”, the BGI Poverty Prevention and Control Committee clearly stated that it seeks to export China’s advanced thalassemia technologies to the countries of the “Belt and Road Initiative”, to jointly achieve comprehensive control of thalassemia. in the global community.
In April 2022, Huada Biotechnology (Wuhan) Co., Ltd. wholly owned by BGI, obtained the medical device registration certificate from the National Drug Administration for the alpha and beta gene detection kit (combining the probe-fixed polymerase chain reaction method).
This agreement was signed by Dr. Faleh Huseynov, Executive Director of the National Center for Hematology and Blood Transfusion, Dr. Agha Reza Agayev, Supervisor of the Department of Medical Genetics in Azerbaijan, and Mr. Jeremy Kao, Vice President of BGI IntDx. The two organizations have entered into a strategic partnership and will work together for a research project to study thalassemia in the country.
“Thank you BGI for your support and cooperation, and I hope this research program will help us build an effective and well-designed method for thalassemia screening,” said Dr.
Azerbaijan is among the countries with the highest prevalence of thalassemia. The Thalassemia Gene Detection Test combines an advanced high-throughput sequencing platform with the advantages of low cost and comprehensive detection. The scientific research partnership assists in comparing methodologies, and promotes new technology collaboration in clinical testing and exploration of thalassemia screening in Azerbaijan. BGI also has a Global Hemoglobin Disease Foundation focused on fighting Thalassemia worldwide, and our goal is to make the world a better place without this disease. Therefore BGI proposes this agreement to reaffirm that we stand with the Azerbaijani Thalassemia Center and its people.”
Zhiyu Peng, Vice President of BGI Genomics
Jeremy Kao, Vice President of BGI IntDx, said at the signing ceremony: “This is one of our pioneering thalassemia projects abroad, and this agreement commits us to work more closely together towards common goals, the pursuit of thalassemia detection and control, and the vision that the future Soon there will be a world free of this disease. I would like to say that I am confident that through our efforts and commitment, we will be able to achieve more and continue to develop stronger relations and friendships between the people of Azerbaijan and BGI.”
Thalassemia, an inherited blood disorder, results from inadequate production of hemoglobin in red blood cells that deliver oxygen and nutrients to all parts of the body. People with thalassemia have much lower hemoglobin than normal people and usually have mild to severe anemia.
The Azerbaijan Thalassemia Center is one of the leading general medical institutions in the fight against Thalassemia in the region. This center not only provides service to patients suffering from this disease, but also offers its services to people with other genetic conditions. The state also provides an institution that provides medical services to foreign citizens in this center.